Q32 Bio Sells Complement Inhibitor ADX-097
Provided By PR Newswire
Last update: Dec 1, 2025
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata --
-- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 --
Read more at prnewswire.com3.18
-0.16 (-4.79%)
1.66
+0.03 (+1.84%)
Find more stocks in the Stock Screener
QTTB Latest News and Analysis
